title: Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
abstract: Malaria remains a serious cause of morbidity and mortality in millions of individuals each year. The development of widespread resistance of the parasite to drugs as well as resistance of the transmitting mosquito-vector to insecticides in combination with the poor economic situation of many malaria-endemic countries make the development of an effective and inexpensive treatment and prevention a main focus of research. Vaccines remain to be one of the most cost effective and feasible means of disease control and have remarkable success in the control of many infectious disease: eradication of small pox, virtual eradication of polio and the reduction of measles and diphtheria. Next generation vaccines should focus on specific antigens rather than whole inactivated or attenuated pathogens, since the requirements by regulatory authorities concerning safety are becoming more stringent over time. But sub-unit and in particular peptide-based vaccines are poorly immunogenic themselves, and alum represents only a sub-optimal adjuvant for recombinant proteins and synthetic peptides. This emphasizes the need for suitable carrier- and adjuvant systems promoting protective immune responses by delivering protein and peptide antigens in an appropriate conformation. Here, we review the development of a new approach combining peptide-based malaria vaccine candidate antigens with an immune stimulatory carrier-system based on influenza virosomes focusing on the induction of protective antibodies.
authors.affiliation: Pevion Biotech Ltd., Bern, Switzerland.
authors.forename: Nicole
authors.initials: N
authors.lastname: Westerfeld
authors.forename: Gerd
authors.initials: G
authors.lastname: Pluschke
authors.forename: Rinaldo
authors.initials: R
authors.lastname: Zurbriggen
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D000953:Antigens, Protozoan / Q000276:immunology*; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D008081:Liposomes; D008213:Lymphocyte Activation / Q000276:immunology; D017780:Malaria Vaccines / Q000276:immunology*; D010455:Peptides / Q000276:immunology; D010961:Plasmodium / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D022721:Vaccines, Virosome / Q000276:immunology*; D022701:Virosomes / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000953:Antigens, Protozoan; D008081:Liposomes; D017780:Malaria Vaccines; D010455:Peptides; D022721:Vaccines, Virosome; D022701:Virosomes